Section
The B-Together phase IIb study demonstrates that sequential therapy with bepirovirsen followed by pegylated interferon-α-2a reduces post-treatment relapse in chronic hepatitis B patients on stable nucleos(t)ide analogue therapy, with enhanc
A comprehensive analysis from the TBTC Study 31/ACTG A5349 reveals that flat dosing of pyrazinamide at 1,000 mg daily optimizes efficacy and safety, challenging current weight-banded dosing strategies for drug-susceptible tuberculosis.
The DETECT Hep C trial demonstrates nontargeted HCV screening in emergency departments identifies more new infections than risk-based approaches, though linkage to care remains suboptimal, underscoring the need for innovative treatment mode
A randomized clinical trial in South Australian long-term care facilities found germicidal UV light appliances did not significantly reduce acute respiratory infection rates per cycle but modestly lowered total infections over time, suggest
A recent multicenter trial demonstrates that a single dose of benzathine penicillin G is noninferior to three doses in treating early syphilis, including patients with HIV, simplifying management and reducing adverse effects.
This longitudinal single-cell multiomics study delineates the evolving immune landscape in HBV-ACLF, identifying key immune cell subsets and signaling pathways that drive disease progression and highlight potential therapeutic targets for p
SCG101, an HBV-specific T-cell receptor T-cell therapy, demonstrates significant antiviral and antitumour efficacy with a manageable safety profile in patients with advanced HBV-related hepatocellular carcinoma refractory to prior treatment
This phase 2 trial demonstrates that azelastine nasal spray reduces SARS-CoV-2 infections and symptomatic respiratory illnesses in a healthy, vaccinated adult population, suggesting its potential as a safe, scalable prophylactic measure aga
A large multicenter study demonstrates that a single dose of RSV vaccine reduces hospitalization risk by 58% among adults aged 60+, with lower effectiveness in immunocompromised and cardiovascular patients.
A recent study shows that over 80% of patients allergic to amoxicillin tolerate piperacillin-tazobactam, though about 18% experience cross-reactivity, highlighting the need for careful allergy testing before use.
A multicountry study across Asia demonstrates soluble TREM1’s superior accuracy over traditional clinical signs in predicting severe febrile illness in children, potentially transforming triage in resource-limited settings.
Long COVID patients exhibit distinct mitochondrial bioenergetic impairments, with altered ATP synthase function correlating with clinical symptoms and quality of life, implicating mitochondrial dysfunction in its pathogenesis.
A 25-year-old woman with recurrent urinary tract infections was diagnosed with unilateral renal agenesis, highlighting the importance of imaging in persistent urinary symptoms.
Iterum Therapeutics has launched Orlynvah, the first oral penem antibiotic approved in the US for uncomplicated urinary tract infections, addressing growing antibiotic resistance.
Kidney-transplant recipients on long-term kidney replacement therapy demonstrate significant reductions in COVID-19-related hospitalizations and mortality following three or more vaccine doses, supporting booster vaccinations in this vulner
Recent rhinovirus infection may nearly halve COVID-19 risk and reduce viral load by triggering airway antiviral gene expression, partially explaining children’s milder COVID-19 outcomes.
A recent Irish study reveals that 6 in 10 healthcare workers with respiratory symptoms test for COVID-19, while vaccination coverage remains low, highlighting ongoing risks and the need for enhanced infection control and vaccination strateg
Observational data from the RECOVER Initiative suggest that SARS-CoV-2 reinfection raises the risk of long COVID by 35% relative to single infections, with more recent vaccination potentially mitigating this risk.
COVID-19 accelerates vascular aging by approximately 5 years, disproportionately affecting women, with vaccination conferring protection primarily in females, highlighting sex-specific immunological responses and long-term vascular risks.
The Stratus variant, known as XFG, now dominates COVID-19 cases in the U.S., complicating recovery efforts amidst rising infections and changing vaccine guidance.
